鼻咽癌（NPC）在世界某些地区仍然是一种地方性疾病，许多患者在诊断时已处于晚期疾病。直到最近几年，化疗仍然是治疗标准，取得的进展甚微。本综述旨在概述治疗这种致命疾病的最新重大突破和即将出现的新策略。本综述重点关注治疗晚期鼻咽癌的有前途的研究药物的最新临床进展。其中包括抗血管药物、信号通路抑制剂和免疫疗法。在铂类化疗中添加免疫检查点抑制剂（CPI）无疑改变了 R/M NPC 的一线治疗格局。这为进一步研究后续治疗方案中的最佳治疗策略留下了很大的空间，可能包括在抗血管药物中添加 CPI 或新型 CPI 组合，无论是否以化疗为骨干。其他潜在的方法包括一线 CPI 联合化疗后的最佳 CPI 维持治疗。即将出现的潜在新药包括抗体药物偶联物、双特异性抗体和信号抑制剂，目前正在进行多项 II/III 期研究。

Nasopharyngeal carcinoma (NPC) remains an endemic disease in certain parts of the world, with many patients presenting with advanced disease on diagnosis. Chemotherapy had remained the standard of care with minimal progress made until recent years. This review aims to provide an overview of recent significant breakthroughs and up-and-coming novel strategies in treating this deadly disease.This review focuses on the latest clinical development of promising investigational agents in the treatment of advanced NPC. These include anti-vascular agents, signaling pathways inhibitors and immunotherapy.The addition of immune-checkpoint inhibitors (CPI) to platinum-based chemotherapy has undoubtedly changed the therapeutic landscape of R/M NPC in the first-line setting. This leaves much room for further research on the optimal treatment strategy in subsequent-line settings, likely including the addition of CPI to anti-vascular agents or novel CPI combinations, with or without chemotherapy as a backbone. Other potential approaches include optimal CPI maintenance therapy after first-line CPI-chemotherapy combination. Potential novel agents on the horizons are antibody-drug conjugates, bi-specific antibodies and signaling inhibitors, with several phase II/III studies currently underway.